FIVE PRIME THERAPEUTICS, INC.
FPRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for FPRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2020.
Tracking 5 pipeline candidates for FIVE PRIME THERAPEUTICS, INC..
Run FIVE PRIME THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available FIVE PRIME THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.25
Lead: Phase 3
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is FIVE PRIME THERAPEUTICS, INC.'s lead drug candidate?
FIVE PRIME THERAPEUTICS, INC.'s most advanced tracked candidate is bemarituzumab (Phase 3) for Gastric or gastroesophageal junction (GEJ) cancer.
Who is the CEO of FIVE PRIME THERAPEUTICS, INC.?
Oyster Point Boulevard is the chief executive officer of FIVE PRIME THERAPEUTICS, INC. (FPRX).
What therapeutic areas does FIVE PRIME THERAPEUTICS, INC. focus on?
FIVE PRIME THERAPEUTICS, INC. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.